In a previous post, I introduced a selection of routine as well as innovative reagents for pluripotent stem cells (iPSC) research. Here, I’d like to present a few more interesting products, with a focus on several manufacturers specialized in this domain: Primorigen, Stemgent and Stemcultures.
Since the discovery of reprogramming factors in 2006 and the boom of CRISPR gene editing strategies, induced pluripotent stem cells (iPSC) have emerged as new cellular models. The development of 3D cell culture technologies has also contributed to the generation of induced Pluripotent Stem Cell (iPSC) derived cells, with unique applications from patient-specific drug responses testing, to regenerative medicine. I would like to introduce in this post a selection of reagents in this domain, a combination of both routine and innovative quality reagents, that I consider as bringing something extra to your stem cell research projects.
Following the start of our recent collaboration with Phenocell, we’re pleased to be able to provide high quality Sebocytes developed from Human induced pluripotent stem cells (iPSC). Thanks to a perfectly standardized reprogramming protocol, they display lower batch to batch variability, allowing better reproducibility and accuracy of your experimental results.
Human induced pluripotent stem (iPS) cells and cells differentiated from iPS cells have widely been used for in vivo models human disease progression. Jason Meyer, of Indiana University Purdue University Indianapolis, uses iPS cell-derived models to study retinogenesis and retinal disease. Two recent papers from his lab highlight the benefits of using Stemgent’s RNA reprogramming technology to enable robust differentiation of iPS cells to the retinal lineage (1, 2). RNA reprogramming technology was chosen in order for these studies to ensure that no vestiges of the reprogramming vectors were retained by the cells or integrated into the genome.